Circulating osteoprotegerin levels and cardiovascular outcomes in patients with pre-dialysis chronic kidney disease: results from the KNOW-CKD study
Abstract While the relationship between circulating osteoprotegerin (OPG) and cardiovascular events is well-established in the general population, its association with cardiovascular risks in chronic kidney disease (CKD) patients remains less robust. This study hypothesized that elevated circulating...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-02-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-024-54335-y |
| _version_ | 1797274756062380032 |
|---|---|
| author | Sang Heon Suh Tae Ryom Oh Hong Sang Choi Chang Seong Kim Eun Hui Bae Seong Kwon Ma Kook-Hwan Oh Kyu-Beck Lee Jong Cheol Jeong Ji Yong Jung Soo Wan Kim The Korean Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD) Investigators |
| author_facet | Sang Heon Suh Tae Ryom Oh Hong Sang Choi Chang Seong Kim Eun Hui Bae Seong Kwon Ma Kook-Hwan Oh Kyu-Beck Lee Jong Cheol Jeong Ji Yong Jung Soo Wan Kim The Korean Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD) Investigators |
| author_sort | Sang Heon Suh |
| collection | DOAJ |
| description | Abstract While the relationship between circulating osteoprotegerin (OPG) and cardiovascular events is well-established in the general population, its association with cardiovascular risks in chronic kidney disease (CKD) patients remains less robust. This study hypothesized that elevated circulating OPG levels might be associated with an increased risk of major adverse cardiac events (MACE) in CKD patients, a total of 2,109 patients with CKD stages 1 through pre-dialysis 5 from the KNOW-CKD cohort were categorized into quartiles based on serum OPG levels. The primary outcome of the study was 3-point MACE, defined as a composite of nonfatal myocardial infarction, nonfatal stroke, or cardiac death. The median follow-up duration was 7.9 years. The cumulative incidence of 3-point MACE significantly varied across serum OPG levels in Kaplan–Meier curve analysis (P < 0.001, log-rank test), with the highest incidence observed in the 4th quartile. Cox regression analysis indicated that, relative to the 1st quartile, the risk of 3-point MACE was significantly higher in the 3rd (adjusted hazard ratio 2.901, 95% confidence interval 1.009 to 8.341) and the 4th quartiles (adjusted hazard ratio 4.347, 95% confidence interval 1.410 to 13.395). In conclusion, elevated circulating OPG levels are associated with adverse cardiovascular outcomes in pre-dialysis CKD patients. |
| first_indexed | 2024-03-07T15:02:51Z |
| format | Article |
| id | doaj.art-ea96f51c6da246bfa3ba96d95bd444f3 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-03-07T15:02:51Z |
| publishDate | 2024-02-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-ea96f51c6da246bfa3ba96d95bd444f32024-03-05T19:03:46ZengNature PortfolioScientific Reports2045-23222024-02-0114111110.1038/s41598-024-54335-yCirculating osteoprotegerin levels and cardiovascular outcomes in patients with pre-dialysis chronic kidney disease: results from the KNOW-CKD studySang Heon Suh0Tae Ryom Oh1Hong Sang Choi2Chang Seong Kim3Eun Hui Bae4Seong Kwon Ma5Kook-Hwan Oh6Kyu-Beck Lee7Jong Cheol Jeong8Ji Yong Jung9Soo Wan Kim10The Korean Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD) InvestigatorsDepartment of Internal Medicine, Chonnam National University Medical School and Chonnam National University HospitalDepartment of Internal Medicine, Chonnam National University Medical School and Chonnam National University HospitalDepartment of Internal Medicine, Chonnam National University Medical School and Chonnam National University HospitalDepartment of Internal Medicine, Chonnam National University Medical School and Chonnam National University HospitalDepartment of Internal Medicine, Chonnam National University Medical School and Chonnam National University HospitalDepartment of Internal Medicine, Chonnam National University Medical School and Chonnam National University HospitalDepartment of Internal Medicine, Seoul National University HospitalDivision of Nephrology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of MedicineDivision of Nephrology, Department of Internal Medicine, Seoul National University Bundang HospitalDivision of Nephrology, Department of Internal Medicine, Gachon University Gil Medical CenterDepartment of Internal Medicine, Chonnam National University Medical School and Chonnam National University HospitalAbstract While the relationship between circulating osteoprotegerin (OPG) and cardiovascular events is well-established in the general population, its association with cardiovascular risks in chronic kidney disease (CKD) patients remains less robust. This study hypothesized that elevated circulating OPG levels might be associated with an increased risk of major adverse cardiac events (MACE) in CKD patients, a total of 2,109 patients with CKD stages 1 through pre-dialysis 5 from the KNOW-CKD cohort were categorized into quartiles based on serum OPG levels. The primary outcome of the study was 3-point MACE, defined as a composite of nonfatal myocardial infarction, nonfatal stroke, or cardiac death. The median follow-up duration was 7.9 years. The cumulative incidence of 3-point MACE significantly varied across serum OPG levels in Kaplan–Meier curve analysis (P < 0.001, log-rank test), with the highest incidence observed in the 4th quartile. Cox regression analysis indicated that, relative to the 1st quartile, the risk of 3-point MACE was significantly higher in the 3rd (adjusted hazard ratio 2.901, 95% confidence interval 1.009 to 8.341) and the 4th quartiles (adjusted hazard ratio 4.347, 95% confidence interval 1.410 to 13.395). In conclusion, elevated circulating OPG levels are associated with adverse cardiovascular outcomes in pre-dialysis CKD patients.https://doi.org/10.1038/s41598-024-54335-yBiomarkerChronic kidney diseaseMajor adverse cardiac eventOsteoprotegerin |
| spellingShingle | Sang Heon Suh Tae Ryom Oh Hong Sang Choi Chang Seong Kim Eun Hui Bae Seong Kwon Ma Kook-Hwan Oh Kyu-Beck Lee Jong Cheol Jeong Ji Yong Jung Soo Wan Kim The Korean Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD) Investigators Circulating osteoprotegerin levels and cardiovascular outcomes in patients with pre-dialysis chronic kidney disease: results from the KNOW-CKD study Scientific Reports Biomarker Chronic kidney disease Major adverse cardiac event Osteoprotegerin |
| title | Circulating osteoprotegerin levels and cardiovascular outcomes in patients with pre-dialysis chronic kidney disease: results from the KNOW-CKD study |
| title_full | Circulating osteoprotegerin levels and cardiovascular outcomes in patients with pre-dialysis chronic kidney disease: results from the KNOW-CKD study |
| title_fullStr | Circulating osteoprotegerin levels and cardiovascular outcomes in patients with pre-dialysis chronic kidney disease: results from the KNOW-CKD study |
| title_full_unstemmed | Circulating osteoprotegerin levels and cardiovascular outcomes in patients with pre-dialysis chronic kidney disease: results from the KNOW-CKD study |
| title_short | Circulating osteoprotegerin levels and cardiovascular outcomes in patients with pre-dialysis chronic kidney disease: results from the KNOW-CKD study |
| title_sort | circulating osteoprotegerin levels and cardiovascular outcomes in patients with pre dialysis chronic kidney disease results from the know ckd study |
| topic | Biomarker Chronic kidney disease Major adverse cardiac event Osteoprotegerin |
| url | https://doi.org/10.1038/s41598-024-54335-y |
| work_keys_str_mv | AT sangheonsuh circulatingosteoprotegerinlevelsandcardiovascularoutcomesinpatientswithpredialysischronickidneydiseaseresultsfromtheknowckdstudy AT taeryomoh circulatingosteoprotegerinlevelsandcardiovascularoutcomesinpatientswithpredialysischronickidneydiseaseresultsfromtheknowckdstudy AT hongsangchoi circulatingosteoprotegerinlevelsandcardiovascularoutcomesinpatientswithpredialysischronickidneydiseaseresultsfromtheknowckdstudy AT changseongkim circulatingosteoprotegerinlevelsandcardiovascularoutcomesinpatientswithpredialysischronickidneydiseaseresultsfromtheknowckdstudy AT eunhuibae circulatingosteoprotegerinlevelsandcardiovascularoutcomesinpatientswithpredialysischronickidneydiseaseresultsfromtheknowckdstudy AT seongkwonma circulatingosteoprotegerinlevelsandcardiovascularoutcomesinpatientswithpredialysischronickidneydiseaseresultsfromtheknowckdstudy AT kookhwanoh circulatingosteoprotegerinlevelsandcardiovascularoutcomesinpatientswithpredialysischronickidneydiseaseresultsfromtheknowckdstudy AT kyubecklee circulatingosteoprotegerinlevelsandcardiovascularoutcomesinpatientswithpredialysischronickidneydiseaseresultsfromtheknowckdstudy AT jongcheoljeong circulatingosteoprotegerinlevelsandcardiovascularoutcomesinpatientswithpredialysischronickidneydiseaseresultsfromtheknowckdstudy AT jiyongjung circulatingosteoprotegerinlevelsandcardiovascularoutcomesinpatientswithpredialysischronickidneydiseaseresultsfromtheknowckdstudy AT soowankim circulatingosteoprotegerinlevelsandcardiovascularoutcomesinpatientswithpredialysischronickidneydiseaseresultsfromtheknowckdstudy AT thekoreancohortstudyforoutcomesinpatientswithchronickidneydiseaseknowckdinvestigators circulatingosteoprotegerinlevelsandcardiovascularoutcomesinpatientswithpredialysischronickidneydiseaseresultsfromtheknowckdstudy |